Close Menu

NEW YORK – Australian genetic testing firm Genetic Technologies said on Wednesday it has entered into definitive agreements with unnamed institutional investors for the purchase of more than 1 million American Depositary Shares at A$1.75 ($1.07) per ADS in a registered direct offering.

Each ADS represents 600 of the firm's ordinary shares, and gross proceeds from the offering, expected to close on or about April 3, is estimated at A$1.8 million ($1.1 million).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.